The price of erdatinib varies significantly depending on the version, strength, and purchase channel. Original drugs (such as the Johnson & Johnson version) are quite expensive, while generic versions are cheaper. Currently, all versions are out-of-pocket and must be purchased through official channels to ensure safety.
I. Original Drug Prices
The original drug manufactured by Johnson & Johnson is not yet widely available in China and is mainly sold through authorized hospitals or pharmacies.
Common strengths include 4mg x 28 tablets and 5mg x 28 tablets. Using the standard dosage, the monthly cost exceeds 30,000 RMB, a heavy financial burden.
Before purchasing, genetic testing is required to confirm FGFR mutation; otherwise, the drug will be ineffective.
II. Generic Drug Prices
Laos version: Lowest price, approximately 800 RMB for 5mg x 28 tablets and approximately 1200 RMB for 4mg x 56 tablets, with a monthly cost of approximately 1200 RMB.
Bangladesh version: Moderate price, approximately 2000+ RMB per box for 4mg x 60 tablets.
Generic drugs have essentially the same ingredients as the original drugs and similar clinical efficacy (e.g., a tumor remission rate of approximately 40.3%), making them suitable for long-term treatment.
III. Purchase Channels and Precautions
Cross-border Medical Institution Direct Mail: Order through reputable overseas platforms, providing drug batch numbers and logistics tracking to ensure safety.
Overseas Self-Purchase: Purchase from reputable hospital pharmacies in Laos, India, etc., with a prescription and retain the purchase receipt.
Avoidance Tips: Be wary of personal purchasing agents and avoid buying low-priced counterfeit drugs; look for anti-counterfeiting labels (such as QR codes verifiable on the official website or laser-engraved packaging).
IV. Medical Insurance and Future Prospects
Currently not included in the national medical insurance catalog, all versions require out-of-pocket payment.
Positive signals include the national government's priority review of drugs for rare diseases, which may lead to their inclusion in medical insurance in the future.
